NeoStem to Acquire CSC in Potential $124M-Plus Stem Cell Deal

NeoStem to Acquire CSC in Potential $124M-Plus Stem Cell Deal

April 14, 2014

Through the deal, NeoStem will take over development of CSC’s Melapuldencel-T, an autologous melanoma initiating (stem) cell immune-based therapy intended to eliminate the tumor cells capable of causing disease recurrence, beginning with the launch of a pivotal Phase III trial.

Click here to read the full article.